Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
FDA grants fast track designation to Tvardi Therapeutics’ TTI-101 for hepatocellular carcinoma
19 October 2022 - Tvardi Therapeutics today announced that its lead product, TTI-101, has been granted fast track designation by the ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 19 Oct 2022
MSAC publishes agenda for February 2023 ESC meeting
19 October 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC ...
Posted by Michael Wonder on 19 Oct 2022
Senator Collins, Representative Eshoo decry Medicare coverage rejection of Alzheimer’s drugs
18 October 2022 - “It’s not CMS’ job to deny the use under the Medicare program of an FDA-approved drug.” – ...
Posted by Michael Wonder on 19 Oct 2022
Evusheld receives Health Canada approval for treatment of COVID-19
18 October 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...
Posted by Michael Wonder on 19 Oct 2022
Women call for 'life-changing' medicinal cannabis oil to be added to Pharmaceutical Benefits Scheme
18 October 2022 - At 79 years old, Trish Fisher still suffers from excruciating pain from a motorbike accident in her ...
Posted by Michael Wonder on 18 Oct 2022
3 in 10 uninsured Americans with diabetes may ration insulin
18 October 2022 - "Universal access to insulin, without cost barriers, is urgently needed." ...
Posted by Michael Wonder on 18 Oct 2022
Axoft brain implant technology is granted FDA breakthrough device designation
18 October 2022 - Axoft today launched and announced FDA breakthrough device designation for its brain-machine interface to better treat ...
Posted by Michael Wonder on 18 Oct 2022
IntelGenx submits response to CRL from FDA for Rizaport VersaFilm
18 October 2022 - IntelGenx today announced that it has responded to the complete response letter for its 505(b)(2) new ...
Posted by Michael Wonder on 18 Oct 2022
Health insurance prices set for takeoff
18 October 2022 - Millions of Americans will find out soon how much their health insurance premiums will increase next ...
Posted by Michael Wonder on 18 Oct 2022
CARsgen announces NDA acceptance of BCMA CAR T zevor-cel (CT053) by China NMPA
18 October 2022 - CARsgen Therapeutics announces that the NMPA of China has accepted the new drug application for zevorcabtagene autoleucel ...
Posted by Michael Wonder on 18 Oct 2022
Department of Health and Aged Care publishes revised agenda for November 2022 PBAC meeting
18 October 2022 - Version 3 notes 9 amendments, including the withdrawal of a resubmission for a new medicine. ...
Posted by Michael Wonder on 18 Oct 2022
MSAC finally recommends genomic testing for certain women with breast cancer
18 October 2022 - A third application from Mryriad Genetics seeking the MBS listing of its gene expression profiling test ...
Posted by Michael Wonder on 18 Oct 2022
Noema Pharma receives FDA fast track designation for basimglurant (NOE-101) in trigeminal neuralgia
18 October 2022 - Noema Pharma today announces that the US FDA has granted fast track designation to its mGluR5 inhibitor ...